arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Nautilus Biotechnology, Inc.

NAUT
$0.90 ▲ +0.02 (+2.06%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
26 Visible periods
16 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nautilus Biotechnology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $114.0M
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share $-0.11
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-14.70M
↑ +11.5%
FCF / Share Free cash flow per share
$-0.11
↑ +4.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
20
Cash Quality
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters